Gilead’s Antibody Finds New Life with $40M Investment in Small Biotech
Gilead, antibody, small biotech, $40M investment, oncology R&D
FDA Expands Approval of Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy to Include Older Boys and Non-Ambulatory Patients
FDA, Sarepta, Duchenne Muscular Dystrophy, Gene Therapy, Elevidys, Ambulatory, Non-Ambulatory, Expanded Approval
Gilead’s Twice-Yearly PrEP Drug Achieves 100% Efficacy in HIV Prevention
Gilead, PrEP, HIV prevention, lenacapavir, GSK, Apretude, HIV vaccine, HIV treatment
Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush
Kyverna, CAR-T, Lupus, Autoimmune Disease, Biotech, Gold Rush, Relapse, Clinical Trials, Gene Therapy
Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio
Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.
Johnson & Johnson to Appeal $150 Million Verdict in HIV Meds Off-Label Marketing Case
Johnson & Johnson, HIV Meds, Off-Label Marketing, Appeal, $150 Million Verdict
FDA Halts BioNTech-MediLink ADC Trial Due to ‘Significant Risk of Illness or Injuries’
FDA, BioNTech, MediLink, ADC, Clinical Trial, Safety Concerns, Cancer Treatment
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
Emergent Biosolutions Sells Baltimore Facility for $30 Million
Emergent Biosolutions, Baltimore facility, sale, Bora, $30 million
Samsung Biologics and Baxter Expand Manufacturing Partnership with $223M Deal
Samsung Biologics, Baxter Healthcare, Manufacturing Deal, $223M, Drug Products, 2034